SCHEMBL10154079

SCHEMBL10154079

CNCc1ccc(N2CCCC2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 2/20 0.75
PRMT6 Q96LA8 1/20 0.62
GAA P10253 7/20 0.53
ALDH1A1 P00352 6/20 0.53
KDM4E B2RXH2 5/20 0.53
MAPT P10636 5/20 0.53
L3MBTL1 Q9Y468 4/20 0.53
ALOX15 P16050 3/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
APP P05067 1/20 0.53
ALOX12 P18054 1/20 0.53
MAPK1 P28482 1/20 0.53
SNCA P37840 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
CHKA P35790 3/20 0.46
HSD17B10 Q99714 2/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
BCHE P06276 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL631505 0.98 NCF1 (0.73) NCF1PRMT6GAAALDH1A1KDM4E
SCHEMBL3440204 0.85 NCF1 (0.87) NCF1PRMT6GAAALDH1A1KDM4E
SCHEMBL631523 0.85 RAB9A (0.62) NCF1PRMT6GAAALDH1A1KDM4E
SCHEMBL16838133 0.83 NCF1 (0.59) NCF1PRMT6ALDH1A1KDM4ELOXL2
SCHEMBL11850922 0.81 TRIM24 (0.56) NCF1GAAALDH1A1KDM4EMAPT
SCHEMBL10154349 0.80 NCF1 (0.56) NCF1PRMT6GAAALDH1A1KDM4E
SCHEMBL20868507 0.80 NCF1 (0.60) NCF1PRMT6GAAALDH1A1KDM4E
SCHEMBL18179874 0.80 NCF1 (0.51) NCF1GAAALDH1A1KDM4EMAPT
SCHEMBL2238765 0.79 NCF1 (0.51) NCF1PRMT6GAAALDH1A1KDM4E
SCHEMBL11859247 0.79 ALDH1A1 (0.57) NCF1GAAALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11014912-B2 Cyanopyrrolidine derivatives with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-05-25 US disclosed
US-20120165309-A1 HETERO RING DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-28 US disclosed
EP-2397479-A1 HETERO RING DERIVATIVE Astellas Pharma Inc. (JP) 2011-12-21 EP disclosed
WO-2010092962-A1 HETERO RING DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11014912-B2 Cyanopyrrolidine derivatives with activity as inhibitors of USP30 USP30, USP39, USP28 NCF1 983/4885PRMT6 792/4885GAA 2219/4885
US-20120165309-A1 HETERO RING DERIVATIVE IL2, PIK3R2, IL2RA NCF1 1832/4885PRMT6 4271/4885GAA 3043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.